S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:RYTM

Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

$43.33
+1.54 (+3.69%)
(As of 03/28/2024 ET)
Today's Range
$41.79
$43.66
50-Day Range
$39.12
$52.44
52-Week Range
$15.50
$52.57
Volume
876,116 shs
Average Volume
585,071 shs
Market Capitalization
$2.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.40

Rhythm Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.4% Upside
$47.40 Price Target
Short Interest
Bearish
15.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
0.43mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$7.61 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.03) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.74 out of 5 stars

Medical Sector

706th out of 939 stocks

Pharmaceutical Preparations Industry

338th out of 444 stocks

RYTM stock logo

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

RYTM Stock Price History

RYTM Stock News Headlines

7 Stocks That Will Drive the Weight Loss Drugs Market (RYTM)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Rhythm City welcomes Banda Maguey
RYTM Dec 2024 40.000 put
RYTM Apr 2024 70.000 call
RYTM Jul 2024 22.500 put
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/29/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RYTM
Employees
226
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.40
High Stock Price Target
$55.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+9.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-184,680,000.00
Net Margins
-238.50%
Pretax Margin
-237.79%

Debt

Sales & Book Value

Annual Sales
$77.43 million
Book Value
$2.87 per share

Miscellaneous

Free Float
57,313,000
Market Cap
$2.61 billion
Optionable
Optionable
Beta
1.90
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

RYTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings
or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price target for 2024?

5 Wall Street analysts have issued 1 year target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $27.00 to $55.00. On average, they expect the company's stock price to reach $47.40 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for RYTM
or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2024?

Rhythm Pharmaceuticals' stock was trading at $45.97 on January 1st, 2024. Since then, RYTM stock has decreased by 5.7% and is now trading at $43.33.
View the best growth stocks for 2024 here
.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our RYTM earnings forecast
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its earnings results on Thursday, February, 22nd. The company reported ($0.70) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.70). The company earned $24.23 million during the quarter, compared to analyst estimates of $25.38 million. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 96.02% and a negative net margin of 238.50%. The company's revenue for the quarter was up 175.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.75) EPS.

What ETFs hold Rhythm Pharmaceuticals' stock?

ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED).

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (13.63%), Goldman Sachs Group Inc. (8.54%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.37%), Federated Hermes Inc. (3.91%) and Perceptive Advisors LLC (3.64%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, William T Roberts and Yann Mazabraud.
View institutional ownership trends
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RYTM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners